Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Trakaki, A; Wolf, P; Weger, W; Eichmann, TO; Scharnagl, H; Stadler, JT; Salmhofer, W; Knuplez, E; Holzer, M; Marsche, G.
Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function.
Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866(7):158943
Doi: 10.1016/j.bbalip.2021.158943
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Marsche Gunther
- Trakaki Athina
- Wolf Peter
- Co-authors Med Uni Graz
- Eichmann Thomas
- Gruden Eva
- Holzer Michael
- Salmhofer Wolfgang
- Scharnagl Hubert
- Stadler Julia
- Weger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Psoriasis is a common chronic inflammatory skin disease linked to increased cardiovascular risk. Functional impairment of high-density lipoprotein (HDL) may contribute to excessive cardiovascular mortality in psoriasis patients. Anti-cytokine therapies with biologics have been efficiently used for the management of psoriasis, however little data is available on the effects of biologic anti-psoriatic therapies on the composition and functionality of HDL. Blood samples were taken from 17 healthy volunteers and from 27 real-world psoriasis patients at baseline (no therapy with biologics) and after short-term (3 to 6 months) and intermediate-term (1 to 2 years) therapy. The biologics used included anti-interleukin (IL)-12/23p40 (ustekinumab), anti-IL17A (secukinumab) or anti-tumor necrosis factor-α (etanercept or adalimumab) antibodies. We observed that in psoriasis patients at baseline, metrics of HDL function including cholesterol efflux capacity of apolipoprotein B-depleted serum (p = 0.021), paraoxonase (p < 0.001) and lecithin-cholesterol acyltransferase (p < 0.001) activities were impaired, when compared to controls. Unexpectedly, we observed that short- and especially intermediate-term therapy with biologics markedly reduced HDL cholesterol efflux capacity (p < 0.001) and rendered HDL pro-inflammatory (p < 0.001), but increased paraoxonase (p = 0.009) and lecithin-cholesterol acyltransferase (p = 0.019) activities. All biologics caused similar changes in HDL composition, subclass distribution and cholesterol efflux capacity. Our results provide evidence that anti-psoriatic therapy with biologic agents is associated with changes in HDL functionality, particle composition and subclass distribution.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Female - administration & dosage
- Humans - administration & dosage
- Lipoproteins, HDL - metabolism
- Male - administration & dosage
- Middle Aged - administration & dosage
- Psoriasis - drug therapy
- Find related publications in this database (Keywords)
- Psoriasis
- Biologics
- HDL
- Cholesterol efflux capacity
- LCAT
- Paraoxonase